目的:評價國產吉西他濱(澤菲)聯合順鉑二線治療晚期乳腺癌的療效和不良反應。方法:34例晚期乳腺癌患者采用國產吉西他濱1000mg/m2,靜脈滴注30min,第1、8天;順鉑25mg/m2,靜脈滴注,第1～3天。21d為一個周期,至少完成兩周期后評價療效。結果:完全緩解2例(588%),部分緩解16例(4706%),總有效率為5294%。中位疾病進展時間為65月,中位生存期為114月;主要不良反應為骨髓抑制和胃腸道反應,所有不良反應在停藥后或對癥處理后均可恢復正常。結論:國產吉西他濱聯合順鉑二線治療晚期乳腺癌療效較好,毒副反應可耐受,值得進一步研究。
Citation：
YAN Jun.. Observation of Domestic Gemcitabine Combined Cisplatin in the Second Line of Treatment of Patients with Metastatic Breast Cancer. West China Medical Journal, 2009, 24(5): 1178-1179. doi:
Copy
Copyright ? the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved
| 1. |
SEIDMAN A D. Gemcitabine as singleagent therapy in the management of advanced breast cancer[J]. Oncology,2001,15(2):1114.
|
| 2. |
張志強,江澤飛,宋三泰.吉西他濱在乳腺癌化療中的臨床應用[J].國外醫學腫瘤學分冊,2003,30(2):132135.
|
| 3. |
RHA S Y, JEUNG H, KIM Y, et al. Efficacy of gemcitabine as a salvage treatment in breast cancer[C]. Proc ASCO,2002,21:A2038.
|
| 4. |
徐從高,張茂宏,楊興季,等,譯.癌—腫瘤學原理與實踐[M].濟南:山東科學技術出版社,2001:15891673.
|
| 5. |
HEINEMAN V. Gemcitabine plus cisplatin for the treatment of metastastic breast cancer[J]. Clin Breast Cancer,2002,3(suppl 1):2429.
|
- 1. SEIDMAN A D. Gemcitabine as singleagent therapy in the management of advanced breast cancer[J]. Oncology,2001,15(2):1114.
- 2. 張志強,江澤飛,宋三泰.吉西他濱在乳腺癌化療中的臨床應用[J].國外醫學腫瘤學分冊,2003,30(2):132135.
- 3. RHA S Y, JEUNG H, KIM Y, et al. Efficacy of gemcitabine as a salvage treatment in breast cancer[C]. Proc ASCO,2002,21:A2038.
- 4. 徐從高,張茂宏,楊興季,等,譯.癌—腫瘤學原理與實踐[M].濟南:山東科學技術出版社,2001:15891673.
- 5. HEINEMAN V. Gemcitabine plus cisplatin for the treatment of metastastic breast cancer[J]. Clin Breast Cancer,2002,3(suppl 1):2429.
